Day: August 7, 2020

Press release (MAR)Malmö, August 7, 2020Acarix AB (publ) publishes Interim Report, January – June 2020Agile and flexible with sustained focus on key prioritiesFor us and for many other companies, the pandemic and global uncertainty have caused delays in some prioritized projects. However, in combination with a dynamic Capital Market this has created a window for us to review our overall funding. The opportunity to secure funding will enable full focus with continued commercialization in priority markets and continued the research as soon as the market is normalized again.Extract from CEO Per Persson’s message to the Interim Report.Second quarter 2020 compared with same period 2019During the second quarter, four CADScor®System (5) and 660 (1,690) disposable patches were sold to end-users. In addition to these systems, six demo systems...

Press release (MAR)Malmö, 7 augusti, 2020Acarix AB (publ) publicerar delårsrapport, januari – juni 2020Adaptiva och flexibla med fokus på prioriteringarFör oss och för många andra företag har pandemin och den globala osäkerheten orsakat förseningar i vissa prioriterade projekt. I kombination med en dynamisk kapitalmarknad har detta dock skapat ett naturligt tillfälle för oss att se över vår finansiering. En säkerställd finansiering skulle möjliggöra fullt fokus på fortsatt kommersialisering på prioriterade marknader och forskning så snart marknaden har normaliserats igen.Utdrag ur VD Per Perssons kommentar till delårsrapporten.Andra kvartalet 2020 jämfört med samma period 2019Under andra kvartalet såldes fyra (5) CADScor®System och 660 (1 690) engångsplåster till slutförbrukare. Utöver dessa system såldes sex demosystem till distributörer...

Basel, Switzerland, August 07, 2020Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the marketing authorization  application (MAA) for the antifungal isavuconazole (Cresemba®) for the treatment of patients with mucormycosis, which was submitted by Basilea’s license partner Pfizer Inc. (NYSE: PFE, “Pfizer”), has been accepted for regulatory review by the Center for Drug Evaluation at the National Medical Products Administration (NMPA) of China.David Veitch, Chief Executive Officer, said: “China is commercially a very important market for Cresemba, accounting for more than 15 percent of the global market for newer antifungals. We are therefore very pleased with the progress Pfizer is making in China, in order to address the unmet medical needs of patients suffering from invasive mold infections.”In November 2017, Basilea and...

Basel, 7. August 2020Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass der von ihrem Lizenzpartner Pfizer Inc. (NYSE: PFE, “Pfizer”) eingereichte Antrag auf Marktzulassung in China für das Antimykotikum Isavuconazol (Cresemba®) zur Behandlung von Patienten mit Mukormykose vom Center for Drug Evaluation bei der chinesischen National Medical Products Administration (NMPA) zur Prüfung angenommen wurde.David Veitch, Chief Executive Officer, sagte: „China ist für Cresemba ein kommerziell sehr wichtiger Markt und macht derzeit mehr als 15 Prozent des Weltmarkts für neuere Antimykotika aus. Wir sind daher sehr zufrieden mit den Fortschritten, die Pfizer in China macht, um die bisher nicht gedeckten medizinischen Bedürfnisse von Patienten mit invasiven Schimmelpilzinfektionen zu adressieren.“Im November 2017 erweiterten Basilea und...

On Thursday 22 October 2020 a General Meeting of Shareholders of ageas SA/NV will be organised to approve the payment of the intermediary dividend of EUR 2.38 per share.Earlier this year Ageas decided to adjust the distribution of its dividend payment of EUR 2.65 per share for the year 2019, taking into account the guidance issued by the National Bank of Belgium on 7 April 2020 in the context of COVID-19.A first dividend payment of EUR 0.27 per share was approved by the General Shareholders’ Meeting of Wednesday 20 May 2020.After careful consideration and taken into account Ageas’ strong and resilient solvency and cash position, the Ageas Board of Directors reconfirms its intention as announced on 8 April 2020, to organise a General Shareholders’ Meeting in October 2020 to approve the payment of the intermediary dividend of...

Le jeudi 22 octobre 2020, une Assemblée générale des Actionnaires d’ageas SA/NV sera organisée en vue d’approuver le paiement du dividende intermédiaire d’EUR 2,38 par action.Au début de cette année, Ageas a décidé d’ajuster la distribution de son paiement de dividende d’EUR 2,65 par action pour l’exercice 2019 compte tenu des orientations publiées par la Banque Nationale de Belgique le 7 avril 2020 dans le contexte pandémique liée au COVID-19.Un premier versement de dividende d’EUR 0,27 par action a été approuvé lors de l’Assemblée générale des Actionnaires du mercredi 20 mai 2020.Après mûre réflexion, et compte tenu de la position solide d’Ageas en matière de solvabilité et de trésorerie, le Conseil d’administration d’Ageas confirme son intention, annoncée le 8 avril 2020, d’organiser une Assemblée générale des Actionnaires en...

Op donderdag 22 oktober 2020 zal de Algemene Vergadering van Aandeelhouders van ageas SA/NV worden gehouden, ter goedkeuring van de betaling van het interim-dividend van 2,38 EUR per aandeel.Begin dit jaar beslist Ageas om de uitkering van zijn dividendbetaling van 2,65 EUR per aandeel voor het jaar 2019 aan te passen, gelet op de prognoses die de Nationale Bank van België op 7 april 2020 bekendmaakte in het kader van Covid-19.Een eerste dividendbetaling van 0,27 EUR per aandeel werd goedgekeurd door de Algemene Vergadering van Aandeelhouders van woensdag 20 mei 2020.Na grondig beraad, en gelet op de sterke en veerkrachtige solvabiliteit en cashpositie van Ageas, bevestigt de Raad van Bestuur opnieuw haar intentie die zij bekendmaakte op 8 april 2020 om een Algemene Vergadering van Aandeelhouders te organiseren in oktober 2020 ter goedkeuring...

 Geneva, Switzerland and Boston, MA –  August 7, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that CEO Ernest Loumaye will present an update on the Company and its pipeline at the Wedbush PacGrow Virtual Healthcare Conference taking place August 11 – 12, 2020.Mr. Loumaye’s presentation will take place on Wednesday August 12, 2020 at 9:45 a.m. Eastern Time (ET).  A live presentation link will be available under “Events Calendar” in the investors section of ObsEva’s website at www.ObsEva.com About ObsEvaObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development,...

Press Release  Regulated Information Inside Information August 7, 2020, 7:00 CETIRVINE, CA and HERSTAL, BELGIUM – August 7, 2020 – MDxHealth SA (Euronext Brussels: MDXH), a commercial-stage innovative molecular diagnostics company, today reports an update and associated delay in obtaining Medicare coverage for its SelectMDx for Prostate Cancer test. In August 2019, Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies under its Molecular Diagnostic Services (MolDx) program, issued a positive draft local coverage determination (LCD) recommending coverage for the SelectMDx test.  Following recent communications with Palmetto GBA related to the retirement of the previously issued draft LCD, the Company has been requested to submit an update to our technical assessment under the MolDx program...

Communiqué de Presse  Information Réglementée. Information Privilégiée. 7 août 2020, 7H00 HECIRVINE, CA et HERSTAL, BELGIQUE – le 7 août 2020 – MDxHealth SA (Euronext Brussels: MDXH), une société de diagnostic moléculaire innovante en phase de commercialisation, annonce aujourd’hui une mise à jour et un retard associé dans l’obtention de la couverture Medicare pour son test SelectMDx for Prostate Cancer.En août 2019, Palmetto GBA, un Entrepreneur Administratif de Medicare (Medicare Administrative Contractor – MAC) qui évalue les technologies de diagnostic moléculaire dans le cadre de son programme de Services de Diagnostic Moléculaire (Molecular Diagnostic Services – MolDx), a publié un projet de détermination de couverture locale (Local Coverage Determination – LCD) positif, recommandant la couverture pour...